Related Experiment Video
Updated: Jul 10, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
[Recent progress in the medical treatment of benign prostatic hyperplasia]
Jean-Nicolas Cornu1, Morgan Rouprêt
1Service d'Urologie de l'Hôpital Pitié-Salpêtrière, Paris, France.
Abstract:
The objectives of medical treatment for benign prostatic hyperplasia (BPH) are multiple: improvement of quality of life, reduction of symptoms, improvement of urine output, and reduction of the risk of acute urinary retention. In addition to validated treatments (alpha1-blockers, 5alpha-reductase inhibitors, plant extracts), new molecules have been added to the therapeutic armamentarium, and combinations of the various available treatments have been tested. The combination of alpha1-blockers and 5alpha-reductase inhibitors has been evaluated, with a significant benefit on symptoms and urodynamic parameters, especially when the prostatic volume exceeds 25 mL. The adverse effects of the combination appear to be comparable to those of monotherapy. The combination of alpha1-blockers and anti-muscarinics appears to be effective in patients with BPH with marked irritative symptoms poorly controlled by alpha1-blockers alone. Finally, a new LH-RH antagonist, improving symptoms and maximum urine flow rate in patients with BPH, could rapidly be made available to urologists.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Calculi III: Medical Management
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
